CORONA REMEDIES
Back to Income Statement
|
CORONA REMEDIES Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Consolidated Net Profit | ₹149 Cr | ₹905 Cr | ₹85 Cr | ₹85 Cr |
What is the latest Consolidated Net Profit of CORONA REMEDIES ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2026 | ₹149 Cr |
| Mar2025 | ₹905 Cr |
| Mar2024 | ₹85 Cr |
| Mar2023 | ₹85 Cr |
How is Consolidated Net Profit of CORONA REMEDIES Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹149 Cr | -83.49 | |
| Mar2025 | ₹905 Cr | 965.63 | |
| Mar2024 | ₹85 Cr | 0.00 | |
| Mar2023 | ₹85 Cr | - | |
Compare Consolidated Net Profit of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹12,388.4 Cr | -0.6% | -3% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹421,539.0 Cr | -1.4% | -6.6% | 7.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹247,576.0 Cr | 1.2% | -2.6% | 60% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹177,251.0 Cr | -2% | -6.1% | 33% | Stock Analytics | |
| CIPLA | ₹105,290.0 Cr | -2.3% | -5.8% | -13.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,752.6 Cr | -1.1% | 3.8% | -5.5% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | -0.6% |
-3% |
|
| SENSEX | 0.8% |
-4.8% |
-10.5% |
You may also like the below Video Courses